Developing innovative treatments designed to improve the everyday lives of women and men
Driving Innovative Research
We aim to develop a targeted approach for diseases of high unmet medical need. Our team is committed to bringing much-needed attention and innovation to women’s health and prostate cancer.
– Lynn Seely, MD, President and Chief Executive Officer
For too long, patients have suffered in the shadows. We are bringing this issue to the light and fighting for a brighter future."
24 May 2019
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
14 May 2019
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
13 May 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids